Trial Profile
A double-blind randomised, placebo-controlled study to evaluate the safety and efficacy of A-60444 [RSV 604] in adults with RSV [respiratory syncytial virus] infection following stem cell transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs RSV 604 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Arrow Therapeutics
- 16 Feb 2010 Actual patient number (27) added as reported by ClinicalTrials.gov.
- 29 Aug 2007 Status changed from recruiting to completed.
- 06 Nov 2005 New trial record.